Biote (BTMD) Cost of Revenue (2021 - 2026)

Biote has reported Cost of Revenue for 6 years, with the latest figure at $14.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 10.88% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $56.2 million (down 1.85% YoY), and the FY2025 full-year result was $54.9 million, down 5.63% from the prior year.
• Cost of Revenue for Q1 2026 stood at $14.0 million, down from $14.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $15.8 million in Q2 2023, with the low at $12.3 million in Q1 2022.
• Average Cost of Revenue over 5 years is $14.1 million, with a median of $14.0 million recorded in 2026.
• Peak annual rise in Cost of Revenue reached 841.21% in 2022, while the deepest fall reached 66.17% in 2022.
• Tracing BTMD's Cost of Revenue over 5 years: stood at $15.4 million in 2022, then retreated by 9.2% to $14.0 million in 2023, then increased by 0.24% to $14.0 million in 2024, then increased by 5.67% to $14.8 million in 2025, then declined by 5.75% to $14.0 million in 2026.
• The last three Cost of Revenue figures came in at $14.0 million (Q1 2026), $14.8 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.

Peer Comparison